June 18, 2018 7:17 PM ET

Biotechnology

Company Overview of Galena Biopharma, Inc.

Company Overview

As of December 29, 2017, Galena Biopharma, Inc. was acquired by SELLAS Life Sciences Group AG, in a reverse merger transaction. Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company develops GALE-401 (anagrelide controlled release), which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination wit...

2000 Crow Canyon Place

Suite 380

San Ramon, CA 94583

United States

Founded in 2003

14 Employees

Phone:

855-855-4253

Fax:

925-498-7799

Key Executives for Galena Biopharma, Inc.

Galena Biopharma, Inc. does not have any Key Executives recorded.

Galena Biopharma, Inc. Key Developments

Galena Biopharma, Inc.(NasdaqCM:SLS) dropped from NASDAQ Composite Index

Galena Biopharma, Inc. has been removed from NASDAQ Composite Index .

Galena Biopharma, Inc. Approves Amendment to Amended and Restated Certificate

Galena Biopharma, Inc. announced that at the Special Meeting of Stockholders held on December 29, 2017 stockholders approved an amendment to the company’s amended and restated certificate of incorporation to effect a reverse stock split of the issued shares of the company’s common stock, at a ratio of not less than 1-for-10 and not greater than 1-for-30, with the exact ratio and effective time of the reverse stock split to be determined by the company’s board of directors and agreed upon by SELLAS and publicly announced by press release.

Galena Biopharma, Inc., Special/Extraordinary Shareholders Meeting, Dec 29, 2017

Galena Biopharma, Inc., Special/Extraordinary Shareholders Meeting, Dec 29, 2017, at 09:00 US Eastern Standard Time. Location: offices of Paul Hastings LLP, 200 Park Avenue NEW YORK United States Agenda: To consider the reverse stock split proposal.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 8, 2017
--
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Galena Biopharma, Inc., please visit www.galenabiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.